IMR Press / FBL / Volume 27 / Issue 11 / DOI: 10.31083/j.fbl2711307
Open Access Original Research
A Promising Target of Langchuangding Prescription Treating Systemic Lupus Erythaematosus Integrated Network Pharmacology with HPLC-MS and Molecular Docking
Show Less
1 School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, 311402 Hangzhou, Zhejiang, China
2 The Second School of Clinical Medicine, Zhejiang Chinese Medical University, 310053 Hangzhou, Zhejiang, China
3 School of Basic Medical Sciences, Zhejiang Chinese Medical University, 310053 Hangzhou, Zhejiang, China
*Correspondence: (Zhijun Xie); (Huiqing Lv)
These authors contributed equally.
Academic Editor: Fazle Elahi
Front. Biosci. (Landmark Ed) 2022, 27(11), 307;
Submitted: 17 June 2022 | Revised: 13 September 2022 | Accepted: 14 October 2022 | Published: 15 November 2022
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Background: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder affecting almost any organ system without effective treatment. Based on accumulating evidence, activated T cells are key cause promoting the pathogenesis of SLE. A traditional clinic Langchuangding formula (LCD) is an effective clinical traditional Chinese medicine prescription for SLE with few side effects and good patient compliance. However, the mechanism of how LCD affects SLE remains unclear. Methods: Targets related to LCD and SLE were predicted and overlapped to construct protein-protein interaction (PPI) for screening core target. Subsequently, flow cytometry analysis and Western-blot method were used to verify the expression levels of target gene in LCD serum treated-Jurkat T cells. The main compounds of LCD were identified by HPLC-MS and further docked with the core targe. Results: 283 protein targets in LCD, 1498 SLE targets and 150 common targets were obtained to construct protein-protein interaction (PPI). Network pharmacology results suggested that LCD was closely related to CASP3 target. To verify the prediction of pharmacological mechanism of LCD treatment for SLE, we investigated the anti-proliferative effects of LCD-treated rat serum on β-oestradiol (300 pg/mL)-activated Jurkat T cells in vitro using a CCK-8 kit and flow cytometry analysis and then analyzed the CASP3 expression levels. Vitro experiments confirmed that LCD serum could suppress the proliferation (p < 0.05) and induce apoptosis of the activated T cells through up-regulating CASP3 expression levels. Interactions between CASP3 target and LCD were further validated integrating HPLC-MS analysis and molecular docking. Conclusions: The results showed that LCD could relieve SLE, which might be attributed to inducing the activated T cells apoptosis by up-regulating CASP3 expression levels. The network pharmacology and molecular docking approach provide a new insight for deepening understanding about TCM. LCD potentially represents a promising therapeutic prescription for SLE supplement treatment with no adverse effects.

systemic lupus erythaematosus
Langchuangding prescription
T cell apoptosis
network pharmacology
Graphic Abstract
View Full Image
81873266/National Natural Science Foundation of China
U21A20402/Key Supported Projects of the Joint Fund of the National Natural Science Foundation of China
81973829/National Natural Science Foundation of China
LY18H270014/Natural Science Foundation of Zhejiang Province
Fig. 1.
Back to top